Biotech entity
Every one of those 1 sits in a single category, pharma. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention JNJ-2113, all published on February 25, 2026.
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention JNJ-2113, all published on February 25, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JNJ-2113. Shared-story counts are live from our verified record — not editorial picks.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
JNJ-2113 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
